Ascendis Pharma
ASND
ASND
241 hedge funds and large institutions have $10.1B invested in Ascendis Pharma in 2025 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 76 increasing their positions, 87 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
241
Holders Change
+30
Holders Change %
+14.22%
% of All Funds
3.27%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.19%
New
54
Increased
76
Reduced
87
Closed
22
Calls
$23.8M
Puts
$38.3M
Net Calls
-$14.5M
Net Calls Change
+$6.32M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$168M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$51.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$51M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$44.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$35.7M |
Top Sellers
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$70.1M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$57.6M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$41.6M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$30.2M |
| 5 |
BlackRock
New York
|
-$21.2M |
